← All indications
Telangiectasia, Hereditary Hemorrhagic
An autosomal dominant vascular anomaly characterized by telangiectases of the skin and mucous membranes and by recurrent gastrointestinal bleeding. This disorder is caused by mutations of a gene (on chromosome 9q3) which encodes endoglin, a membrane glycoprotein that binds TRANSFORMING GROWTH FACTOR BETA.
Drugs by status
Phase 4 trials (1)
Phase 3 trials (6)
Phase 2 trials (10)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (27)
- Schering-Plough
- GlaxoSmithKline
- Unity Health Toronto
- University of Pittsburgh
- Barrow Neurological Institute
- Harvard University
- Duke University
- Radboud University
- RTI International
- University of Pavia
- University of Toronto
- Mayo Clinic
- Tel Aviv University
- University of British Columbia
- University of California, San Diego
- University of Vienna
- Feinstein Institute for Medical Research
- Department of Defense
- St. Antonius Hospital, Nieuwegein
- Technion University
- University of North Carolina at Chapel Hill
- University of Massachusetts
- Washington University in St. Louis
- Department of Veteran Affairs
- Hereditary Hemorrhagic Telangiectasia Foundation International
- University of Caen-Normandie
- The Cleveland Clinic
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (6)